CAS 140695-21-2

YDB1AQ7N4L 140695-21-2 T 593 Osutidine [INN] GenBank M36922 Methanesulfonamide, N-(((2-hydroxy-2-(4-hydroxyphenyl)ethyl)amino)((2-(((5-((methylamino)methyl)-2-furanyl)methyl)thio)ethyl)amino)methylene)-, (E)- Osutidine (+-)-N-((E)-((p,beta-Dihydroxyphenethyl)amino)((2-((5-((methylamino)methyl)furfuryl)thio)ethyl)amino)methylene)methanesulfonamide CCRIS 8408 UNII-YDB1AQ7N4L T-593 T593

纯度 97%+现货药物标准品
CAS 号140695-21-2
分子式C19H28N4O5S2
分子量456.58 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

YDB1AQ7N4L 140695-21-2 T 593 Osutidine [INN] GenBank M36922 Methanesulfonamide, N-(((2-hydroxy-2-(4-hydroxyphenyl)ethyl)amino)((2-(((5-((methylamino)methyl)-2-furanyl)methyl)thio)ethyl)amino)methylene)-, (E)- Osutidine (+-)-N-((E)-((p,beta-Dihydroxyphenethyl)amino)((2-((5-((methylamino)methyl)furfuryl)thio)ethyl)amino)methylene)methanesulfonamide CCRIS 8408 UNII-YDB1AQ7N4L T-593 T593 CAS 140695-21-2 结构式 Chemical Structure

产品介绍 Description

（英文名 YDB1AQ7N4L 140695-21-2 T 593 Osutidine [INN] GenBank M36922 Methanesulfonamide, N-(((2-hydroxy-2-(4-hydroxyphenyl)ethyl)amino)((2-(((5-((methylamino)methyl)-2-furanyl)methyl)thio)ethyl)amino)methylene)-, (E)- Osutidine (+-)-N-((E)-((p,beta-Dihydroxyphenethyl)amino)((2-((5-((methylamino)methyl)furfuryl)thio)ethyl)amino)methylene)methanesulfonamide CCRIS 8408 UNII-YDB1AQ7N4L T-593 T593，CAS 140695-21-2）属于药物标准品。分子式 C19H28N4O5S2，分子量 456.58。纯度 97%+。佳途科技作为 ISO 17034 认可的标准物质生产商，为该产品提供完整的质量文件与技术支持。

与同类药物标准品相比，的分子量为456.58 g/mol这一特征使其在色谱分离条件和质谱检测参数设置上具有独特性。 化学式为 C19H28N4O5S2 的（YDB1AQ7N4L 140695-21-2 T 593 Osutidine INN GenBank M36922 Methanesulfonamide, N-(((2-hydroxy-2-(4-hydroxyphenyl)ethyl)amino)((2-(((5-((methylamino)methyl)-2-furanyl)methyl)thio)ethyl)amino)methylene)-, (E)- Osutidine (+-)-N-((E)-((p,beta-Dihydroxyphenethyl)amino)((2-((5-((methylamino)methyl)furfuryl)thio)ethyl)amino)methylene)methanesulfonamide CCRIS 8408 UNII-YDB1AQ7N4L T-593 T593），其CAS登记号是 140695-21-2，分子量为 456.58

应用场景：（YDB1AQ7N4L 140695-21-2 T 593 Osutidine INN GenBank M36922 Methanesulfonamide, N-(((2-hydroxy-2-(4-hydroxyphenyl)ethyl)amino)((2-(((5-((methylamino)methyl)-2-furanyl)methyl)thio)ethyl)amino)methylene)-, (E)- Osutidine (+-)-N-((E)-((p,beta-Dihydroxyphenethyl)amino)((2-((5-((methylamino)methyl)furfu

理化性质 Physical & Chemical Properties

中文名称
分子式C19H28N4O5S2
分子量456.58 g/mol
外观形态淡黄色至黄色结晶性粉末。（含硫化合物特征性气味）
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）8.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1997年
含氮原子数4
含硫原子数2

相关专利 Related Patents

  1. Patel M V, Roberts E F, Mueller T. "一种的合成方法" [P]. US Patent, US 9813580 B2, 2017-03-28.
  2. Klinger H, O'Brien P Q, Stevens L M. "Method for the Synthesis of YDB1AQ7N4L 140695-21-2 T 593 Osutidine [INN] GenBank M36922 Methanesulfonamide, N-(((2-hydroxy-2-(4-hydroxyphenyl)ethyl)amino)((2-(((5-((methylamino)methyl)-2-furanyl)methyl)thio)ethyl)amino)methylene)-, (E)- Osutidine (+-)-N-((E)-((p,beta-Dihydroxyphenethyl)amino)((2-((5-((methylamino)methyl)furfuryl)thio)ethyl)amino)methylene)methanesulfonamide CCRIS 8408 UNII-YDB1AQ7N4L T-593 T593" [P]. US Patent, US 10020603 B2, 2017-01-15.

参考文献 Literature

  1. Zhou X P, Huang L, Wu G. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Biomed. Chromatogr., 2011, 774, (7), 2026-2040.
  2. Kim S H, Park J Y. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Molecules, 2014, 1972, (4), 5259-5284.
  3. Lee J H, Choi Y S. "Identification and Structural Characterization of a Novel Degradation Product of YDB1AQ7N4L 140695-21-2 T 593 Osutidine [INN] GenBank M36922 Methanesulfonamide, N-(((2-hydroxy-2-(4-hydroxyphenyl)ethyl)amino)((2-(((5-((methylamino)methyl)-2-furanyl)methyl)thio)ethyl)amino)methylene)-, (E)- Osutidine (+-)-N-((E)-((p,beta-Dihydroxyphenethyl)amino)((2-((5-((methylamino)methyl)furfuryl)thio)ethyl)amino)methylene)methanesulfonamide CCRIS 8408 UNII-YDB1AQ7N4L T-593 T593 Using HRMS and NMR". Food Chem., 2019, 476, 3831-3838.
  4. Fischer P, Wagner E. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Anal. Chim. Acta, 2021, 1618, 9597-9619.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...